SLS Stock Price, SELLAS Life Sciences Group Quote, Chart

Market Summary

USD1.470.00

Market Closed

0.00%

SLS Stock Price

View Fullscreen

SLS RSI Chart

SLS Valuation

Market Cap

84.9M

Price/Earnings (Trailing)

-2.37

Price/Sales (Trailing)

78.55

EV/EBITDA

-1.8

Price/Free Cashflow

-2.82

SLS Price/Sales (Trailing)

SLS Profitability

Operating Margin

-58.60%

EBT Margin

-3734.00%

Return on Equity

-369.77%

Return on Assets

-146.55%

Free Cashflow Yield

-35.42%

SLS Fundamentals

SLS Revenue

Revenue (TTM)

1.0M

SLS Earnings

Earnings (TTM)

-35.8M

Earnings Growth (Yr)

13.8%

Earnings Growth (Qtr)

-17.58%

Breaking Down SLS Revenue

Last 7 days

8.1%

Last 30 days

4.3%

Last 90 days

90.9%

Trailing 12 Months

-13.5%

How does SLS drawdown profile look like?

SLS Financial Health

Current Ratio

1.49

SLS Investor Care

Shares Dilution (1Y)

103.74%

Diluted EPS (TTM)

-1.09

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	2.9M	1.0M	1.0M	1.0M
2021	3.3M	4.8M	6.2M	7.6M
2020	0	0	0	1.9M
2015	9.9M	10.9M	0	0
2014	9.3M	9.3M	9.3M	9.3M
2013	0	7.0M	7.4M	9.3M
2012	0	0	0	0
2011	0	0	0	0
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of SELLAS Life Sciences Group Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 22, 2024	kalin katherine bach	acquired	-	-	6,000	-
Jan 22, 2024	francomano robert	acquired	-	-	20,000	chief commercial officer
Jan 22, 2024	stergiou angelos m.	acquired	-	-	159,000	president and ceo
Jan 22, 2024	burns john thomas	acquired	-	-	47,000	cfo
Jan 22, 2024	varian john	acquired	-	-	6,000	-
Jan 22, 2024	wasman jane	acquired	-	-	6,000	-
Jan 22, 2024	scheinberg david a	acquired	-	-	6,000	-
Jan 22, 2024	van nostrand robert l	acquired	-	-	6,000	-
Jan 22, 2024	wood barbara a	acquired	-	-	35,000	evp, gen. counsel, corp. sec.
Dec 06, 2023	francomano robert	sold	-1,168	1.08	-1,082	chief commercial officer

Which funds bought or sold SLS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-11,913	-	-%
May 15, 2024	CITADEL ADVISORS LLC	new	-	19,915	19,915	-%
May 15, 2024	Royal Bank of Canada	reduced	-37.71	-	-	-%
May 15, 2024	CANTOR FITZGERALD, L. P.	new	-	24,998	24,998	0.01%
May 15, 2024	Mariner, LLC	new	-	25,510	25,510	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-16,222	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	287	15,257	20,932	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	sold off	-100	-869,200	-	-%
May 15, 2024	Engineers Gate Manager LP	sold off	-100	-17,868	-	-%
May 15, 2024	Nemes Rush Group LLC	unchanged	-	-500	10,100	-%

Are Funds Buying or Selling SLS?

Are funds buying SLS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SLS

No. of Funds

Unveiling SELLAS Life Sciences Group Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 07, 2024	highbridge capital management llc	6.5%	2,080,054	SC 13G
Feb 16, 2021	cvi investments, inc.	2.7%	315,249	SC 13G/A
Feb 12, 2021	packer paul	1.2%	141,553	SC 13G/A
Dec 14, 2020	hirschman orin	1.5%	190,000	SC 13G/A
Sep 21, 2020	packer paul	5.3%	497,391	SC 13G
Aug 25, 2020	hirschman orin	9.9%	936,735	SC 13G
Feb 14, 2020	altium capital management lp	1.1%	56,000	SC 13G/A
Feb 14, 2020	anson funds management lp	-	0	SC 13G/A
Feb 13, 2020	683 capital management, llc	1%	38,000	SC 13G/A
Feb 13, 2020	renaissance technologies llc	0.00%	0	SC 13G/A

Recent SEC filings of SELLAS Life Sciences Group Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
May 01, 2024	EFFECT	EFFECT
May 01, 2024	EFFECT	EFFECT
Apr 30, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 29, 2024	S-3/A	S-3/A
Mar 29, 2024	D	D
Mar 28, 2024	10-K	Annual Report

Peers (Alternatives to SELLAS Life Sciences Group Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

SELLAS Life Sciences Group Inc News

Latest updates

SELLAS Life Sciences Group Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2015Q2	2015Q1	2014Q4	2014Q3	2014Q2	2014Q1	2013Q4	2013Q3	2013Q2	2013Q1	2012Q4
Revenue	-	-	-	-	-	1,000,000	-	-	1,900,000	5,700,000	4,541,000	3,382,000	2,750,000	3,195,000	1,620,000	2,331,000	2,173,000	3,195,000	1,620,000	2,331,000	2,173,000	1,317,000
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	-	468,000	393,000	478,000	247,000	347,000	331,000	262,000	258,000	-	-	-
Costs and Expenses	-13.4%	8,177,000	9,446,000	7,146,000	8,623,000	17,735,000	11,619,000	6,977,000	6,353,000	7,945,000	6,059,000	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6,130,000	7,762,000	7,986,000	6,611,000	5,578,000
S&GA Expenses	-14.4%	3,080,000	3,600,000	2,864,000	3,094,000	3,024,000	2,526,000	2,436,000	2,797,000	3,561,000	3,288,000	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	-	-	-	-	-	-	3,393,000	4,541,000	3,456,000	4,284,000	2,771,000	-	-	-	-	-	-	-	-	-	-	-
EBITDA Margin	10.2%	-36.83	-41.00	-20.79	-20.90	-7.22	-2.76	-2.72	-3.53	-5.05	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-74.1%	41,000	158,000	111,000	46,000	2,000	-	2,000	2,000	2,000	1,000	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	9.6%	-37.34	-41.30	-20.94	-20.94	-7.22	-2.75	-2.72	-3.53	-5.04	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	10.8%	-8,136,000	-9,121,000	-7,022,000	-8,414,000	-16,744,000	-6,598,000	-7,085,000	-4,613,000	-2,403,000	-3,716,000	-	-	-	-	-	-	-	-	-	-	-
Net Income Margin	9.6%	-37.34	-41.30	-38.78	-38.84	-12.08	-2.72	-2.89	-3.20	-4.52	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	6.3%	-4,825,000	-5,152,000	-5,746,000	-5,761,000	-7,150,000	-4,976,000	-5,878,000	-4,898,000	-10,269,000	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	292.9%	24.00	6.00	8.00	19.00	29.00	21.00	26.00	32.00	21.00	26.00	38.00	44.00	41.00	46.00	19.00	15.00	17.00	17.00	21.00	25.00	15.00
Current Assets	577.8%	22.00	3.00	5.00	16.00	26.00	18.00	23.00	29.00	18.00	23.00	29.00	35.00	31.00	37.00	9.00	5.00	9.00	8.00	10.00	14.00	3.00
Cash Equivalents	631.8%	19.00	3.00	4.00	14.00	24.00	17.00	21.00	27.00	14.00	21.00	26.00	30.00	28.00	35.00	8.00	3.00	7.00	7.00	9.00	13.00	3.00
Goodwill	0.7%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Liabilities	3.9%	15.00	14.00	12.00	14.00	16.00	16.00	13.00	13.00	17.00	6.00	11.00	10.00	12.00	18.00	11.00	11.00	9.00	11.00	11.00	11.00	12.00
Current Liabilities	5.1%	14.00	14.00	12.00	13.00	16.00	16.00	13.00	12.00	11.00	5.00	5.00	4.00	6.00	12.00	4.00	4.00	4.00	5.00	6.00	5.00	6.00
Shareholder's Equity	221.4%	10.00	-7.98	-	5.00	13.00	5.00	13.00	19.00	4.00	20.00	27.00	33.00	29.00	28.00	8.00	4.00	8.00	6.00	11.00	14.00	3.00
Retained Earnings	-4.4%	-226	-217	-209	-199	-191	-179	-170	-163	-155	-138	-132	-124	-120	-117	-114	-109	-105	-101	-93.73	-89.53	-86.39
Additional Paid-In Capital	13.0%	236	209	205	205	204	185	183	183	159	159	159	158	149	146	122	113	113	107	104	104	89.00
Shares Outstanding	75.1%	56.00	32.00	28.00	28.00	28.00	21.00	19.00	18.00	16.00	16.00	16.00	15.00	15.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	44.00	-	-	-	46.00	-	-	-	176	-	-	-	20.00	-	-	-	11.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-123.0%	-10,761	-4,825	-6,892	-7,593	-12,100	-5,152	-5,746	-5,761	-7,150	-4,976	-5,878	-4,898	-10,269	3,424	-3,629	-3,381	-6,831	-4,176	-3,820	-4,656	-4,991
Share Based Compensation	-4.2%	476	497	543	514	540	446	455	450	375	288	275	264	184	141	146	146	145	147	115	126	185
Cashflow From Investing	-	-	-	-3,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cashflow From Financing	686.9%	26,646	3,386	54.00	-29.00	18,904	929	107	22,996	47.00	50.00	2,242	6,782	3,000	23,675	8,492	-25.00	6,300	2,319	189	14,831	2,230
Dividend Payments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SLS Income Statement

2024-03-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 5,111	$ 7,174
General and administrative	4,534	4,107
Total operating expenses	9,645	11,281
Loss from operations	(9,645)	(11,281)
Non-operating income:
Change in fair value of warrant liability	0	2
Interest income	79	182
Total non-operating income	79	184
Net loss	$ (9,566)	$ (11,097)
Per share information:
Net loss per common share, basic (in dollars per share)	$ (0.21)	$ (0.47)
Net loss per common share, diluted (in dollars per share)	$ (0.21)	$ (0.47)
Weighted-average common shares outstanding, basic (in shares)	44,812,996	23,547,562
Weighted-average common shares outstanding, diluted (in shares)	44,812,996	23,547,562

SLS Balance Sheet

2024-03-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 18,415	$ 2,530
Restricted cash and cash equivalents	100	100
Prepaid expenses and other current assets	2,986	542
Total current assets	21,501	3,172
Operating lease right-of-use assets	747	858
Goodwill	1,914	1,914
Deposits and other assets	272	275
Total assets	24,434	6,219
Current liabilities:
Accounts payable	7,407	5,639
Accrued expenses and other current liabilities	6,542	7,650
Operating lease liabilities	488	446
Total current liabilities	14,437	13,735
Operating lease liabilities, non-current	313	460
Total liabilities	14,750	14,195
Commitments and contingencies (Note 7)
Stockholders’ (deficit) equity:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; Series A convertible preferred stock, 17,500 shares designated; no shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value; 350,000,000 shares authorized, 56,267,670 and 32,132,890 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	5	3
Additional paid-in capital	236,489	209,265
Accumulated deficit	(226,810)	(217,244)
Total stockholders’ equity (deficit)	9,684	(7,976)
Total liabilities and stockholders’ equity (deficit)	$ 24,434	$ 6,219

About SELLAS Life Sciences Group Inc

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.

CEO	Dr. Angelos M. Stergiou M.D., ScD h.c.
WEBSITE	sellaslifesciences.com
INDUSTRY	Biotechnology
EMPLOYEES	17

SELLAS Life Sciences Group Inc Frequently Asked Questions

What is the ticker symbol for SELLAS Life Sciences Group Inc? What does SLS stand for in stocks?

SLS is the stock ticker symbol of SELLAS Life Sciences Group Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of SELLAS Life Sciences Group Inc (SLS)?

As of Fri May 17 2024, market cap of SELLAS Life Sciences Group Inc is 84.9 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SLS stock?

You can check SLS's fair value in chart for subscribers.

What is the fair value of SLS stock?

You can check SLS's fair value in chart for subscribers. The fair value of SELLAS Life Sciences Group Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of SELLAS Life Sciences Group Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SLS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is SELLAS Life Sciences Group Inc a good stock to buy?

The fair value guage provides a quick view whether SLS is over valued or under valued. Whether SELLAS Life Sciences Group Inc is cheap or expensive depends on the assumptions which impact SELLAS Life Sciences Group Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SLS.

What is SELLAS Life Sciences Group Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, SLS's PE ratio (Price to Earnings) is -2.37 and Price to Sales (PS) ratio is 78.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SLS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on SELLAS Life Sciences Group Inc's stock?

In the past 10 years, SELLAS Life Sciences Group Inc has provided -0.656 (multiply by 100 for percentage) rate of return.